AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Biotica

Biotica is a privately-held biotechnology company that discovers and develops polyketide therapeutics. It has a growing pipeline of novel therapeutic programmes supported by clinical validation. These include nPT-mTOR (unique mTOR inhibitors partnered with Pfizer), nPT-CyP (cyclophilin inhibitors for HCV) and nPT-ery (anti-inflammatory erythromycin analogues partnered with GlaxoSmithKline). All of Biotica’s projects employ its proprietary novoPT™ technology, which enables it to select from the many known polyketides with biological activity and make a range of derivatives that are either difficult or impossible to make by medicinal chemistry methods. For additional information visit www.biotica.com.

GSK

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies.  The application of Chemical Biology represents a significant advancement that is helping to improve the design of new medicines, better understand the patient’s needs and enhance the benefit from tomorrow’s therapies.  Support for the continued development of Chemical Biology will  help GlaxoSmithKline in its stated mission, to improve the quality of human life by enabling people to do more, feel better and live longer.

Imagen Biotech

Every day we produce high quality data which is used by the pharmaceutical industry to better understand their lead compounds, by SMEs to add critical information to their research portfolio and by academics to greatly enhance their publication rate. We can conduct every aspect of a High Content Screen no matter how large or small. Our catalogue is full of powerful cell-based assays which will provide an unparalleled source of information on how your compounds are behaving within a cellular context. Our assays allow the detailed analysis of signal transduction pathways and target validation. We support key phenotypic assays including apoptosis, neurite outgrowth and cytoskeletal structure. Finally, we possess our own unique program for creating workbooks to contain your data as well as a carefully defined pricing structure that allows you to choose which options to include in your study thereby maximising the information you receive for any given budget.

Morvus

Morvus Technology Ltd is a pharmaceutical company based in Carmarthenshire, South Wales. The company specialises in the discovery and commercialisation of novel drugs. We currently have a number of agents that are in clinical development and several ‘in-house’ research projects.  Our main focus is in the oncology field, but other areas of interest include CNS, anti-parasitic and biofuels. Morvus collaborates with a number of universities and other institutions to develop therapeutic agents for the clinic. We have expertise and state-of-the-art facilities in medicinal chemistry, analytical biochemistry and cell biology.  For further information visit http://www.morvus.com

Oxyrane

Oxyrane has its headquarters in Manchester and operations in Manchester and Ghent (Belgium). External collaborations include research projects with Professors Flitsch and Turner (MIB). The Company’s technology platform allows for the rapid development, optimisation and production of a wide range of glycoproteins, based on a proprietary integrated recombinant expression system that was purpose built for the yeast Yarrowia lipolytica. Inter alia, glycol-engineered strains haqve been developed to produce lysosomal storage disease (LSD) enzyme replacement therapies with high efficiency. Other materials that have been produced using this new platform include erythropoietin, neuraminidase, interferon alpha-2b as well as antibodies in scFv, FAB and IgG format.

Peakdale Molecular

Peakdale Molecular offers a class-leading range of products and services to its pharmaceutical and biotechnology customers to accelerate their drug discovery initiatives.  At its very core, Peakdale's approach is based upon its long & successful track record of problem-solving within our customers' discovery projects. Peakdale is renowned for completing difficult synthetic organic and medicinal chemistry against time & cost constraints for customers big and small the world over. Whether it is process development, small molecule discovery programme that needs computational, chemistry & ADME services or "design & make" projects for scaffolds & synthons, Peakdale offers flexible, creative and confidential support for your discovery project. For further information please visit

Senexis

Senexis is a small-molecule drug discovery and development company that is committed to the treatment and diagnosis of diseases resulting from the inevitable process of ageing. Senexis is advancing a pipeline of novel treatments for diseases resulting from the toxicity of amyloid-like proteins with a particular focus on Alzheimer’s disease.  The company’s research programmes rely on a number of scientific disciplines and the Manchester Chemical Biology Network will provide an excellent opportunity to provide assistance and exchange of information in areas of mutual interest and to build on the already strong links that Senexis has with Manchester University.

Syngenta

Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life.  For more information about us please go to www.syngenta.com.

Manchester Biomedical Research Centre